Logo

Bioverge

Bioverge is a healthcare venture capital platform democratizing access to cutting-edge innovation.

San Francisco, CA, USA

Apply

Description

Bioverge is a venture capital investment platform based in San Francisco, California, that specializes in early-stage healthcare startups at the intersection of biology and technology (TechBio). It operates as an alternative investment platform, democratizing access for accredited individuals and institutions to invest in highly-vetted healthcare innovations. While not a traditional cohort-based accelerator, founders typically submit their ventures for a rigorous vetting process involving scientific and financial diligence before being featured on the platform for syndication.
  • Seed and Series A: Bioverge primarily targets emerging healthcare startups at these early institutional stages.
  • Investment Types: It offers three main investment vehicles: Access Funds (diversified portfolios of 15+ startups), Deal-By-Deal (direct investment in individual companies), and Thematic Funds (focused on specific technologies like longevity or diseases like cancer)

Eligibility

  • Sectors: Biotechnology, Digital Health, Medical Devices, AI, Gene Therapy, and Longevity.
  • Investors: Must meet U.S. accredited investor criteria.
  • Startups: Generally high-impact tech-driven healthcare companies solving major challenges. 

Process

  1. Vetting: Startups undergo a proprietary review process where only a small percentage of highly-vetted "top institution" caliber deals are accepted.
  2. Syndication: Accepted deals are presented to Bioverge members, with individual investment minimums outlined in each deal profile.
  3. Post-Investment: Bioverge acts as a passive investment vehicle, often accepting terms from lead investors. It provides quarterly performance updates and distributes income or shares upon a successful exit. 

What an Applicant can Obtain

  • For Founders: Capital from a syndicate of up to 99 accredited investors per deal.
  • For Investors: Exposure to high-potential healthcare startups previously reserved for large VC firms.